The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E–Deficient Mice—Brief Report
Open accessAbstract
Objective—: Inflammasomes are multiprotein complexes, and their activation has been associated with cardiovascular disease. Inflammasome activation leads to secretion of caspase-1 by innate immune cells, resulting in the activation of interleukin-1β. Recently, a potent and selective inhibitor of the NLRP3 inflammasome, MCC950, was described. In this study, we investigated the effect of MCC950 on atherosclerotic lesion development in apoE −/− mice. Approach and Results—: First, we determined the efficacy of MCC950 in vitro. Bone marrow–derived macrophages and dendritic cells were stimulated with lipopolysaccharide and cholesterol crystals resulting in high levels of interleukin-1β release, which was inhibited by MCC950. In vivo MCC950 treatment reduced lipopolysaccharide–induced interleukin-1β secretion, without affecting the tumor necrosis factor-α response. Subsequently, atherosclerotic plaques were induced in Western-type diet fed apoE −/− mice by semiconstrictive perivascular collar placement at the carotid arteries, after which the mice received MCC950 (10 mg/kg) or vehicle control 3× per week intraperitoneally for 4 weeks. After euthanize, atherosclerotic plaque size and volume were quantified in hematoxylin-eosin–stained 10-µm cryosections throughout the artery. MCC950 treatment significantly reduced the development of atherosclerotic lesions as determined by maximal stenosis, average plaque size, and plaque volume. Although the amount of collagen and the necrotic core size were not affected, the number of macrophages in the plaque was significantly reduced on treatment. In addition, VCAM-1 (vascular cell adhesion molecule 1) and ICAM-1 (intercellular adhesion molecule 1) mRNA expression was significantly reduced in the carotids of MCC950-treated mice. Conclusions—: These findings show that specific inhibition of the NLRP3 inflammasome using MCC950 can be a promising therapeutic approach to inhibit atherosclerotic lesion development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a mouse model of atherosclerosis, the inhibition of the NLRP3 inflammasome by MCC950 resulted in a significant reduction in atherosclerotic lesions [82].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [82]
In the citing paper
“Inhibition of the nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome (NLRP3) suppressed T-cell senescence57 and atherosclerosis.58”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [58]
In the citing paper
“Human atherosclerotic lesions show increased expression of the major components of NLRP3 (REF 61), and inhibition of the NLRP3 inflammasome reduces atherosclerosis in Apoe−/− mice62.”
From Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities (2019) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases
Coll, R. C., Robertson, A. A. B., Chae, J. J., Higgins, S. C., Muñoz-Planillo, R., Inserra, M. C., Vetter, I., Dungan, L. S., Monks, B. G., Stutz, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3806 · Cited by 2,849
NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?
Tschopp, J., & Schroder, K. (2010) · Nature reviews. Immunology · doi:10.1038/nri2725 · Cited by 1,859
Agostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., & Tschopp, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00046-9 · Cited by 1,768
Rajamäki, K., Lappalainen, J., Öörni, K., Välimäki, E., Matikainen, S., Kovanen, P. T., & Eklund, K. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011765 · Cited by 1,039
Ridker, P. M., Thuren, T., Zalewski, A., & Libby, P. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.06.012 · Cited by 799
The inflammasome: an integrated view
Gross, O., Thomas, C. J., Guarda, G., & Tschopp, J. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01046.x · Cited by 778
Lack of Interleukin-1β Decreases the Severity of Atherosclerosis in ApoE-Deficient Mice
Kirii, H., Niwa, T., Yamada, Y., Wada, H., Saito, K., Iwakura, Y., Asano, M., Moriwaki, H., & Seishima, M. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000064374.15232.c3 · Cited by 748
IL-1α and IL-1β Recruit Different Myeloid Cells and Promote Different Stages of Sterile Inflammation
Rider, P., Carmi, Y., Guttman, O., Braiman, A., Cohen, I., Voronov, E., White, M. R., Dinarello, C. A., & Apte, R. N. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102048 · Cited by 546
Cited by
Sorted by citations
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
Swanson, K. V., Deng, M., & Ting, J. P.-Y. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0165-0 · Cited by 4,884
Targeting the NLRP3 inflammasome in inflammatory diseases
Mangan, M. S. J., Olhava, E. J., Roush, W. R., Seidel, H. M., Glick, G. D., & Latz, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.97 · Cited by 1,885
Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities
Bäck, M., Yurdagul, A., Tabas, I., Öörni, K., & Kovanen, P. T. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0169-2 · Cited by 1,341
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
Kong, P., Cui, Z.-Y., Huang, X.-F., Zhang, D.-D., Guo, R.-J., & Han, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00955-7 · Cited by 1,183
Xu, S., Ilyas, I., Little, P. J., Li, H., Kamato, D., Zheng, X., Luo, S., Li, Z., Liu, P., Han, J., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000096 · Cited by 1,205
Targeting inflammation in atherosclerosis — from experimental insights to the clinic
Soehnlein, O., & Libby, P. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00198-1 · Cited by 1,085
NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis
Grebe, A., Hoss, F., & Latz, E. (2018) · Circulation Research · doi:10.1161/circresaha.118.311362 · Cited by 926
Peng, Y., Ao, M., BaoHua, D., Jiang, Y., Yu, L., Chen, Z., Hu, C.-J., & Xu, R. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s327378 · Cited by 916
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
Abbate, A., Toldo, S. A., Marchetti, C., Kron, J., Tassell, B. W. V., & Dinarello, C. A. (2020) · Circulation Research · doi:10.1161/circresaha.120.315937 · Cited by 769
Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
Ridker, P. M., & Rane, M. A. (2021) · Circulation Research · doi:10.1161/circresaha.121.319077 · Cited by 743
Interleukin-1 Beta as a Target for Atherosclerosis Therapy
Libby, P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.028 · Cited by 651
Blevins, H. M., Xu, Y., Biby, S., & Zhang, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.879021 · Cited by 587
How the immune system shapes atherosclerosis: roles of innate and adaptive immunity
Roy, P., Orecchioni, M., & Ley, K. F. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00584-1 · Cited by 610
Targeting cardiovascular inflammation: next steps in clinical translation
Lawler, P. R., Bhatt, D. L., Godoy, L. C., Lüscher, T. F., Bonow, R. O., Verma, S., & Ridker, P. M. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa099 · Cited by 463
Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?
Engelen, S. E., Robinson, A., Zurke, Y.-X., & Monaco, C. G. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00668-4 · Cited by 455
The NLRP3 inflammasome: Mechanism of action, role in disease and therapies
Wang, L., & Hauenstein, A. V. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100889 · Cited by 426
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases
Toldo, S. A., & Abbate, A. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00946-3 · Cited by 461
Targeting the NLRP3 Inflammasome in Severe COVID-19
Freeman, T. L., & Swartz, T. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01518 · Cited by 413
Martínez, G. J., Celermajer, D. S., & Patel, S. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.12.027 · Cited by 356
Targeting the NLRP3 inflammasome in cardiovascular diseases
Toldo, S. A., Mezzaroma, E., Buckley, L. F., Potere, N., Nisio, M. D., Biondi‐Zoccai, G., Tassell, B. W. V., & Abbate, A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108053 · Cited by 346
Cell death pathways: intricate connections and disease implications
Kist, M., & Vucic, D. (2021) · The EMBO Journal · doi:10.15252/embj.2020106700 · Cited by 337
Neuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review
Cheng, R., Wu, Z., Li, M., Shao, M., & Hu, T. (2020) · International Journal of Oral Science · doi:10.1038/s41368-019-0068-8 · Cited by 304
Krishnan, S. M., Ling, Y. H., Huuskes, B. M., Ferens, D. M., Saini, N., Chan, C. T., Diep, H., Kett, M. M., Samuel, C. S., Kemp‐Harper, B. K., et al. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy252 · Cited by 287
Ward, R., Li, W., Abdul, Y., Jackson, L., Dong, G., Jamil, S., Filosa, J. A., Fagan, S. C., & Ergul, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.035 · Cited by 276
Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis
Ridker, P. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313129 · Cited by 260
“In ApoE-deficient mice, the selective NLRP3 inhibitor MCC950 has shown reduced development of atherosclerotic lesions, as well as ICAM and VCAM mRNA expression.(118) MCC950 also reduces infarct size and preserves ventricular function in pig models of myocardial infarction and has shown efficacy in the treatment of inf…”
BackgroundTherapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome
Li, H., Guan, Y., Liang, B., Ding, P., Hou, X., Wei, W., & Ma, Y. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175091 · Cited by 258
Ma, Q. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000629 · Cited by 260
Livshits, G., & Kalinkovich, A. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100980 · Cited by 245
Anti-inflammatory potential of Quercetin in COVID-19 treatment
Saeedi‐Boroujeni, A., & Mahmoudian‐Sani, M. (2021) · Journal of Inflammation · doi:10.1186/s12950-021-00268-6 · Cited by 240
Inflammasomes as therapeutic targets in human diseases
Li, Y., Huang, H., Liu, B., Zhang, Y. L., Pan, X., Yu, X., Shen, Z., & Song, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00650-z · Cited by 238
The NLRP3 inflammasome in traumatic brain injury: potential as a biomarker and therapeutic target
O’Brien, W. T., Pham, L., Symons, G. F., Monif, M., Shultz, S. R., & McDonald, S. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01778-5 · Cited by 233
Therapeutic modulation of inflammasome pathways
Chauhan, D., Walle, L. V., & Lamkanfi, M. (2020) · Immunological Reviews · doi:10.1111/imr.12908 · Cited by 219
Jha, J. C., Ho, F., Dan, C., & Jandeleit-Dahm, K. A. M. (2018) · Clinical Science · doi:10.1042/cs20171459 · Cited by 207
Programmed death of macrophages in atherosclerosis: mechanisms and therapeutic targets
Meyer, G. R. Y. D., Zurek, M., Puylaert, P., & Martinet, W. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00957-0 · Cited by 221
The NLRP3 Inflammasome: Metabolic Regulation and Contribution to Inflammaging
Meyers, A. K., & Zhu, X. (2020) · Cells · doi:10.3390/cells9081808 · Cited by 207
Oxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes
Charlton, A., Garzarella, J., Jandeleit-Dahm, K. A. M., & Jha, J. C. (2020) · Biology · doi:10.3390/biology10010018 · Cited by 214
Zeng, W., Wu, D., Sun, Y., Suo, Y., Yu, Q., Zeng, M., Gao, Q., Yu, B., Jiang, X., & Wang, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-98437-3 · Cited by 196
Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis
Stojanović, S. D., Fiedler, J., Bauersachs, J., Thum, T., & Sedding, D. G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz919 · Cited by 188
Endothelial Foxp1 Suppresses Atherosclerosis via Modulation of Nlrp3 Inflammasome Activation
Zhuang, T., Liu, J., Chen, X., Zhang, L., Pi, J., Sun, H., Li, L., Bauer, R. C., Wang, H., Yu, Z., et al. (2019) · Circulation Research · doi:10.1161/circresaha.118.314402 · Cited by 188
NLRP3 inflammasome as a key driver of vascular disease
Takahashi, M. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab010 · Cited by 193
Gomez‐Lopez, N., Galaz, J., Miller, D., Farías, M., Liu, Z., Arenas‐Hernandez, M., Garcia‐Flores, V., Shaffer, Z., Greenberg, J. M., Theis, K. R., et al. (2022) · Reproduction · doi:10.1530/rep-22-0046 · Cited by 194
Corcoran, S. E., Halai, R., & Cooper, M. A. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000171 · Cited by 180
Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease
Shahzad, K., Fatima, S., Khawaja, H., Elwakiel, A., Gadi, I., Ambreen, S., Zimmermann, S., Mertens, P. R., Biemann, R., & Isermann, B. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.010 · Cited by 184
Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk
Ridker, P. M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.082 · Cited by 186
Gao, R., Shi, H., Chang, S., Gao, Y., Li, X., Lv, C., Yang, H., Xiang, H., Yang, J., Xu, L., et al. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.04.022 · Cited by 180
Baik, S. H., Ramanujan, V. K., Becker, C. A., Fett, S., Underhill, D. M., & Wolf, A. J. (2023) · Science Immunology · doi:10.1126/sciimmunol.ade7652 · Cited by 193
Impact of intracellular innate immune receptors on immunometabolism
Chou, W.-C., Rampanelli, E., Li, X., & Ting, J. P. ‐. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00780-y · Cited by 173
Botts, S. R., Fish, J. E., & Howe, K. L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.787541 · Cited by 181
Inflammation as a Therapeutic Target in Atherosclerosis
Nguyen, M. T., Fernando, S., Schwarz, N., Tan, J. T. M., Bursill, C. A., & Psaltis, P. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081109 · Cited by 176
Targeting the Inflammasome in Cardiovascular Disease
Olsen, M. B., Gregersen, I., Sandanger, Ø., Yang, K., Sokolova, M., Halvorsen, B. L., Gullestad, L. L., Broch, K., Aukrust, P., & Louwe, M. C. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.08.006 · Cited by 178
Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review
Wu, D., Chen, Y., Sun, Y., Gao, Q., Li, H., Yang, Z., Wang, Y., Jiang, X., & Yu, B. (2019) · Inflammation · doi:10.1007/s10753-019-01098-8 · Cited by 163
The Dynamics of B Cell Aging in Health and Disease
de Mol, J., Kuiper, J., Tsiantoulas, D., & Foks, A. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.733566 · Cited by 159
Self-citationNovel Insights Into the NLRP3 Inflammasome in Atherosclerosis
Jin, Y. H., & Fu, J. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012219 · Cited by 153
Specific NLRP3 Inhibition Protects Against Diabetes-Associated Atherosclerosis
Sharma, A., Choi, J. S. Y., Stefanovic, N., Al‐Sharea, A., Simpson, D. S., Mukhamedova, N., Jandeleit-Dahm, K. A. M., Murphy, A. J., Sviridov, D., Vince, J. E., et al. (2020) · Diabetes · doi:10.2337/db20-0357 · Cited by 140
Endothelial shear stress signal transduction and atherogenesis: From mechanisms to therapeutics
He, L., Zhang, C., Chen, Q., Wang, L., & Huang, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108152 · Cited by 141
Inflammasome biology, molecular pathology and therapeutic implications
Awad, F., Assrawi, E., Louvrier, C., Jumeau, C., Georgin‐Lavialle, S., Grateau, G., Amselem, S., Giurgea, I., & Karabina, S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.011 · Cited by 138
Romacho, T., Valencia, I., Ramos-González, M., Vallejo, S., López‐Esteban, M., Lorenzo, Ó., Cannata, P., Romero, A., Hipólito‐Luengo, Á. S., Gómez-Cerezo, J. F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-62190-w · Cited by 139
Zhang, X., Wang, Z., Zheng, Y., Yu, Q., Zeng, M., Bai, L., Yang, L., Guo, M., Jiang, X., & Gan, J. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5238 · Cited by 144
Zhang, L., Jiang, Y.-H., Fan, C., Zhang, Q., Jiang, Y.-H., Li, Y., & Xue, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112133 · Cited by 129
New Dawn for Atherosclerosis: Vascular Endothelial Cell Senescence and Death
Bu, L.-L., Yuan, H., Xie, L., Guo, M.-H., Liao, D., & Zheng, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015160 · Cited by 133
Ren, P., Wu, D., Appel, R., Zhang, L., Zhang, C., Luo, W., Robertson, A. A. B., Cooper, M. A., Coselli, J. S., Milewicz, D. M., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014044 · Cited by 128
Zhang, C., Zhu, X., Li, L., Ma, T., Shi, M., Yang, Y., & Fan, Q. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s199802 · Cited by 119
Su, Z., Li, C., Wang, H., Zheng, M., & Chen, Q. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04270-9 · Cited by 126
Intra-amniotic inflammation induces preterm birth by activating the NLRP3 inflammasome†
Faro, J. P., Romero, R. J., Schwenkel, G., Garcia‐Flores, V., Arenas‐Hernandez, M., Leng, Y., Xu, Y., Miller, D., Hassan, S. S., & Gomez‐Lopez, N. (2018) · Biology of Reproduction · doi:10.1093/biolre/ioy261 · Cited by 115
Chronic low‐grade inflammation in heart failure with preserved ejection fraction
Mesquita, T., Lin, Y., & Ibrahim, A. G.-E. (2021) · Aging Cell · doi:10.1111/acel.13453 · Cited by 118
Ma, Q., Fan, Q., Han, X., Dong, Z., Xu, J., Bai, J., Tao, W., Sun, D., & Wang, C. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.11.064 · Cited by 112
Interleukin-1β suppression dampens inflammatory leucocyte production and uptake in atherosclerosis
Hettwer, J., Hinterdobler, J., Miritsch, B., Deutsch, M.-A., Li, X., Mauersberger, C., Moggio, A., Braster, Q., Gram, H., Robertson, A. A. B., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab337 · Cited by 118
Stressing out the mitochondria: Mechanistic insights into NLRP3 inflammasome activation
Yabal, M., Calleja, D. J., Simpson, D. S., & Lawlor, K. E. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0318-124r · Cited by 110
Alehashemi, S., & Goldbach‐Mansky, R. T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01840 · Cited by 108
Liu, S., Bi, Y., Han, T., Li, Y. E., Wang, Q., Wu, N. N., Xu, C., Ge, J., Hu, R., & Zhang, Y. (2024) · Cell Discovery · doi:10.1038/s41421-023-00622-3 · Cited by 112
Gomez‐Lopez, N., Romero, R. J., Garcia‐Flores, V., Leng, Y., Miller, D., Hassan, S. S., Hsu, C., & Panaitescu, B. (2018) · Biology of Reproduction · doi:10.1093/biolre/ioy264 · Cited by 105
Chen, S., Wang, Y., Pan, Y., Liu, Y., Zheng, S., Ding, K., Mu, K., Yuan, Y., Li, Z., Song, H., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015513 · Cited by 101
Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies
Lee, Y. A., & Friedman, S. L. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13380 · Cited by 104
Inflammasomes and Proteostasis Novel Molecular Mechanisms Associated With Atrial Fibrillation
Li, N., & Brundel, B. J. J. M. (2020) · Circulation Research · doi:10.1161/circresaha.119.316364 · Cited by 98
Inflammation as A Precursor of Atherothrombosis, Diabetes and Early Vascular Aging
Barbu, E., Popescu, M.-R., Popescu, A.-C., & Balanescu, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020963 · Cited by 96
Colchicine prevents accelerated atherosclerosis in TET2 -mutant clonal haematopoiesis
Zuriaga, M. A., Yu, Z., Matesanz, N., Truong, B. M. T., Ramos-Neble, B. L., Lopez, M., Uddin, M. M., Nakao, T., Niroula, A., Zorita, V., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae546 · Cited by 98
Thromboinflammation: From Atherosclerosis to COVID-19
Wagner, D. D., & Heger, L. A. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317162 · Cited by 95
IL-1 family cytokines in cardiovascular disease
Pfeiler, S., Winkels, H., Kelm, M., & Gerdes, N. (2017) · Cytokine · doi:10.1016/j.cyto.2017.11.009 · Cited by 88
Lipid and Non-lipid Factors Affecting Macrophage Dysfunction and Inflammation in Atherosclerosis
Gibson, M. S., Domingues, N. S., & Vieira, O. V. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00654 · Cited by 82
Chen, S., Zhou, Y., Wang, X., Sun, J., Cao, F., HaiSam, S., Ye, D., & Tian, Y. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104339 · Cited by 86
Bakhshi, S., & Shamsi, S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108595 · Cited by 85
Suciu, C. F., Prete, M., Ruscitti, P., Favoino, E., Giacomelli, R., & Perosa, F. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.11.028 · Cited by 84
Highlighting Residual Atherosclerotic Cardiovascular Disease Risk
Matsuura, Y., Kanter, J. E., & Bornfeldt, K. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311999 · Cited by 88
Circadian Control of Inflammasome Pathways: Implications for Circadian Medicine
Pourcet, B., & Duez, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01630 · Cited by 88
The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches
Tsioufis, P., Theofilis, P., Tsioufis, K. P., & Tousoulis, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415937 · Cited by 93
Bai, R., Lang, Y., Shao, J., Deng, Y., Refuhati, R., & Cui, L. (2021) · ASN NEURO · doi:10.1177/17590914211018100 · Cited by 86
Inflammasomes: Pandora’s box for sepsis
Kumar, V. (2018) · Journal of Inflammation Research · doi:10.2147/jir.s178084 · Cited by 88
Targeting NLRP3 Inflammasome Reduces Age-Related Experimental Alveolar Bone Loss
Zang, Y., Song, J. H., Oh, S., Kim, J. W., Lee, M. N., Piao, X., Yang, J.-W., Kim, O. S., Kim, T. S., Kim, S. H., et al. (2020) · Journal of Dental Research · doi:10.1177/0022034520933533 · Cited by 81
NLRP3 inflammasome and IL-1β pathway in type 2 diabetes and atherosclerosis: Friend or foe?
Chen, X., Zhang, D., Li, Y., Wang, W., Bei, W., & Guo, J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105885 · Cited by 84
Nuclear Receptors in the Control of the NLRP3 Inflammasome Pathway
Duez, H., & Pourcet, B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.630536 · Cited by 85
From Mitochondria to Atherosclerosis: The Inflammation Path
Suarez-Rivero, J. M., Pastor‐Maldonado, C. J., Povea-Cabello, S., Álvarez-Córdoba, M., Villalón-García, I., Talaverón-Rey, M., Suárez-Carrillo, A., Munuera-Cabeza, M., & Sánchez-Alcázar, J. A. (2021) · Biomedicines · doi:10.3390/biomedicines9030258 · Cited by 78
Dai, Z., Chen, X.-Y., An, L.-Y., Li, C., Zhao, N., Yang, F., You, S.-T., Hou, C., Li, K., Jiang, C., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01924 · Cited by 76
NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases
Mezzaroma, E., Abbate, A., & Toldo, S. A. (2021) · Molecules · doi:10.3390/molecules26040976 · Cited by 79
NLRP3 Inflammasome Mediates Immune-Stromal Interactions in Vasculitis
Porritt, R. A., Zemmour, D., Abe, M., Lee, Y., Narayanan, M., de Carvalho, T. T., Gomez, A. C., Martinon, D., Santiskulvong, C., Fishbein, M. C., et al. (2021) · Circulation Research · doi:10.1161/circresaha.121.319153 · Cited by 76
Pyroptosis in development, inflammation and disease
Pan, Y., Cai, W., Huang, J., Cheng, A., Wang, M., Yin, Z., & Jia, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991044 · Cited by 74
The strategies of targeting the NLRP3 inflammasome to treat inflammatory diseases
Jiang, H., Gong, T., & Zhou, R. (2019) · Advances in immunology · doi:10.1016/bs.ai.2019.11.003 · Cited by 71
Tang, F., Kunder, R., Chu, T., Hains, A., Nguyen, A., McBride, J. M., Zhong, Y., Santagostino, S., Wilson, M., Trenchak, A., et al. (2023) · Clinical and Translational Science · doi:10.1111/cts.13576 · Cited by 70
NLRP3 Inflammasome/Pyroptosis: A Key Driving Force in Diabetic Cardiomyopathy
Zhang, L., Ai, C., Bai, M., Niu, J., & Zhang, Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810632 · Cited by 73
Hadri, K. E., Smith, R., Duplus, E., & Amri, C. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010077 · Cited by 71
Metadata
- Authors
- van der Heijden, T., Kritikou, E., Venema, W., van Duijn, J., van Santbrink, P. J., Slütter, B., Foks, A. C., Bot, I., & Kuiper, J.
- Affiliations
- From the Cluster BioTherapeutics, LACDR, Leiden University, The Netherlands.
- Leiden University (NL)
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2017-08
- Volume
- 37
- Issue
- 8
- Pages
- 1457-1461
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2623847043
- Cited by
- 348
- References
- 21
- Citations by year
- 2026: 25 · 2025: 28 · 2024: 35 · 2023: 49 · 2022: 47 · 2021: 66 · 2020: 40 · 2019: 29 · 2018: 24 · 2017: 4
- FWCI
- 10.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- European Commission
- ZonMw
- Servier
- Nederlandse Federatie van Universitair Medische Centra
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- NLRP3 inflammasome, MCC950, atherosclerosis, atherosclerotic plaque, ApoE-deficient mice, IL-1β, caspase-1, macrophages, dendritic cells, VCAM-1, ICAM-1, carotid artery stenosis, anti-inflammatory therapy
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Anti-Inflammatory Agents, Apolipoproteins E, Carotid Arteries, Carotid Artery Diseases, Cells, Cultured, Cholesterol, Crystallization, Dendritic Cells, Disease Models, Animal, Female, Furans, Heterocyclic Compounds, 4 or More Rings, Indenes, Lipopolysaccharides, Macrophages, Mice, Inbred C57BL, Necrosis, Phenotype, RNA, Messenger, Sulfonamides, Sulfones, Time Factors, Signal Transduction, Mice, Knockout, Intercellular Adhesion Molecule-1, Vascular Cell Adhesion Molecule-1, Genetic Predisposition to Disease, Atherosclerosis, Interleukin-1beta, Plaque, Atherosclerotic, Inflammasomes, Diet, Western
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
